[en] A deficit of mitochondrial energy metabolism may play a role in migraine pathogenesis. We found in a previous open study that high-dose riboflavin was effective in migraine prophylaxis. We now compared riboflavin (400 mg) and placebo in 55 patients with migraine in a randomized trial of 3 months duration. Using an intention-to-treat analysis, riboflavin was superior to placebo in reducing attack frequency (p = 0.005) and headache days (p = 0.012). Regarding the latter, the proportion of patients who improved by at least 50%, i.e. "responders," was 15% for placebo and 59% for riboflavin (p = 0.002) and the number-needed-to-treat for effectiveness was 2.3. Three minor adverse events occurred, two in the riboflavin group (diarrhea and polyuria) and one in the placebo group (abdominal cramps). None was serious. Because of its high efficacy, excellent tolerability, and low cost, riboflavin is an interesting option for migraine prophylaxis and a candidate for a comparative trial with an established prophylactic drug.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Jacquy, J.
Lenaerts, M.
Language :
English
Title :
Effectiveness of High-Dose Riboflavin in Migraine Prophylaxis. A Randomized Controlled Trial
Publication date :
February 1998
Journal title :
Neurology
ISSN :
0028-3878
eISSN :
1526-632X
Publisher :
Lippincott Williams & Wilkins, United States - Maryland
Welch KMA, Levine SR, D'Andrea G, Schultz L, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31phosphorus NMR spectroscopy. Neurology 1989;39:538-541.
Montagna P, Sacquegna T, Cortelli P, Lugaresi E. Migraine as a defect of brain oxidative metabolism: a hypothesis. J Neurol 1989;236:124-125.
Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992;42:1209-1214.
Montagna P, Cortelli P, Monari L, et al. 31P-Magnetic resonance spectroscopy in migraine without aura. Neurology 1994; 44:666-668.
Sangiorgi S, Mochi M, Riva R, et al. Abnormal platelet mitochrondrial function in patients affected by migraine with and without aura. Cephalalgia 1994;14:21-23.
Watanabe H, Kuwabara T, Ohkubo M, Tsuji S, Yuasa T. Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996;47:1093-1095.
Montagna P, Gallassi R, Medori R, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1988;38:751-754.
Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992;42:545-550.
Arts WFM, Scholte HR, Boggard JM, Kerrebijn KF, Luyt-Houwen IEM. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 1983;2:581-582.
Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitocriondrial tRNALeu (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-2152.
Antozzi C, Garavaglia B, Mora M, et al. Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme. A dehydrogenase and respiratory chain deficiency. Neurology 1994;44:2153-2158.
Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994;14:328-329.
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1-96.
International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia 1991;11:1-12.
McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br Med J 1995;311:1047-1052.
Armitage P, Berry G. Statistical methods in medical research, 3rd ed. Oxford: Blackwell Scientific Publications, 1994.
Andersson KE, Vinge E. β-Adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990;39:355-373.
Toda N, Tfelt-Hansen P. Calcium Antagonists. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The headache. New York: Raven Press, 1993.
Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44:647-651.
Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:2481-2486.
Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257-263.
Diener HC, Föh M, Iaccarino C, et al. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. Cephalalgia 1996;16:441-447.
Klopstock T, May A, Seibel P, Papagiannuli E, Diener HC, Reichmann H. Mitochondrial DNA in migraine with aura. Neurology 1996;46:1735-1738.
Levy G, Mosovich LL, Allen JE, Yaffe SJ. Biliary excretion of riboflavin in man. J Pharm Sci 1972;61:143-144.
